Biobehavioral and Interpersonal Predictors of Cognitive Impairment in Older Adults With Type 2 Diabetes: A Systematic Review of Cohort Studies.

Biol Res NursApr 18, 2026 (epub)
Clinical ResearchGeriatricsEndocrinology

Min Jung Kim, Bohyun Kim

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed cohort studies to identify predictors of cognitive impairment in older adults with type 2 diabetes. It included 43 studies and found that higher HbA1c levels, glucose variability, and severe hypoglycemia significantly predicted cognitive impairment risk. The review emphasizes the importance of addressing diabetes-specific biological markers and health behaviors in prevention strategies.

Key findings

  • Higher HbA1c levels significantly predicted increased cognitive impairment risk.
  • Severe hypoglycemia was associated with a higher risk of cognitive decline.
  • Poor diet and low physical activity were linked to cognitive impairment.
  • Limited social contact was connected to a higher risk of dementia.

Why it matters

Understanding the predictors of cognitive impairment in older adults with type 2 diabetes is crucial for developing targeted prevention strategies. Addressing modifiable risk factors can help mitigate cognitive decline and improve patient outcomes.

Source

PubMed · PMID 41999513

Published in Biol Res Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.